Christian S Stohler

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7392997/publications.pdf

Version: 2024-02-01

55 papers	8,840 citations	101543 36 h-index	155660 55 g-index
55 all docs	55 docs citations	55 times ranked	8030 citing authors

#	Article	IF	Citations
1	Effects of placebo administration on immune mechanisms and relationships with central endogenous opioid neurotransmission. Molecular Psychiatry, 2022, 27, 831-839.	7.9	5
2	Role of the Prefrontal Cortex in Pain Processing. Molecular Neurobiology, 2019, 56, 1137-1166.	4.0	397
3	Âμ-Opioid Activity in Chronic TMD Pain Is Associated with COMT Polymorphism. Journal of Dental Research, 2019, 98, 1324-1331.	5.2	13
4	Role of prefrontal cortical calcium-independent phospholipase A 2 in antinociceptive effect of the norepinephrine reuptake inhibitor antidepresssant maprotiline. Neuroscience, 2017, 340, 91-100.	2.3	5
5	Chronic Back Pain Is Associated with Alterations in Dopamine Neurotransmission in the Ventral Striatum. Journal of Neuroscience, 2015, 35, 9957-9965.	3.6	137
6	Effects of the Mu Opioid Receptor Polymorphism (OPRM1 A118G) on Pain Regulation, Placebo Effects and Associated Personality Trait Measures. Neuropsychopharmacology, 2015, 40, 957-965.	5.4	125
7	Dynamic Interactions Between Plasma IL-1 Family Cytokines and Central Endogenous Opioid Neurotransmitter Function in Humans. Neuropsychopharmacology, 2015, 40, 554-565.	5.4	23
8	FAAH selectively influences placebo effects. Molecular Psychiatry, 2014, 19, 385-391.	7.9	77
9	Valence-Specific Effects ofBDNFVal⁶⁶Met Polymorphism on Dopaminergic Stress and Reward Processing in Humans. Journal of Neuroscience, 2014, 34, 5874-5881.	3.6	54
10	Neurobiology of placebo effects: expectations or learning?. Social Cognitive and Affective Neuroscience, 2014, 9, 1013-1021.	3.0	45
11	Personality Trait Predictors of Placebo Analgesia and Neurobiological Correlates. Neuropsychopharmacology, 2013, 38, 639-646.	5.4	160
12	DRD2 polymorphisms modulate reward and emotion processing, dopamine neurotransmission and openness to experience. Cortex, 2013, 49, 877-890.	2.4	106
13	Alterations in Endogenous Opioid Functional Measures in Chronic Back Pain. Journal of Neuroscience, 2013, 33, 14729-14737.	3.6	57
14	Leptin Regulates Dopamine Responses to Sustained Stress in Humans. Journal of Neuroscience, 2012, 32, 15369-15376.	3.6	48
15	Comprehensive Gene Expression Profiling in the Prefrontal Cortex Links Immune Activation and Neutrophil Infiltration to Antinociception. Journal of Neuroscience, 2012, 32, 35-45.	3.6	35
16	Oxytocin Gene Polymorphisms Influence Human Dopaminergic Function in a Sex-Dependent Manner. Biological Psychiatry, 2012, 72, 198-206.	1.3	87
17	Striatal Dopamine Release and Genetic Variation of the Serotonin 2C Receptor in Humans. Journal of Neuroscience, 2012, 32, 9344-9350.	3.6	41
18	Emotion Processing, Major Depression, and Functional Genetic Variation of Neuropeptide Y. Archives of General Psychiatry, 2011, 68, 158.	12.3	100

#	Article	IF	Citations
19	Pain Imaging in the Emerging Era of Molecular Medicine. Methods in Molecular Biology, 2010, 617, 517-537.	0.9	6
20	Zhou et al. reply. Nature, 2009, 458, E7-E7.	27.8	1
21	Neurobiological Mechanisms of Placebo Responses. Annals of the New York Academy of Sciences, 2009, 1156, 198-210.	3.8	220
22	Positron Emission Tomography Measures of Endogenous Opioid Neurotransmission and Impulsiveness Traits in Humans. Archives of General Psychiatry, 2009, 66, 1124.	12.3	87
23	Genetic variation in human NPY expression affects stress response and emotion. Nature, 2008, 452, 997-1001.	27.8	387
24	Placebo and Nocebo Effects Are Defined by Opposite Opioid and Dopaminergic Responses. Archives of General Psychiatry, 2008, 65, 220.	12.3	553
25	Individual Differences in Reward Responding Explain Placebo-Induced Expectations and Effects. Neuron, 2007, 55, 325-336.	8.1	392
26	The End of an Era: Orofacial Pain Enters the Genomic Age. Pain and Headache, 2007, , 236-247.	0.1	3
27	Time-course of change in [11C]carfentanil and [11C]raclopride binding potential after a nonpharmacological challenge. Synapse, 2007, 61, 707-714.	1.2	59
28	Belief or Need? Accounting for individual variations in the neurochemistry of the placebo effect. Brain, Behavior, and Immunity, 2006, 20, 15-26.	4.1	97
29	TMJD 3: A Genetic Vulnerability Disorder With Strong CNS Involvement. Journal of Evidence-based Dental Practice, 2006, 6, 53-57.	1.5	8
30	Pronociceptive and Antinociceptive Effects of Estradiol through Endogenous Opioid Neurotransmission in Women. Journal of Neuroscience, 2006, 26, 5777-5785.	3.6	287
31	Variations in the Human Pain Stress Experience Mediated by Ventral and Dorsal Basal Ganglia Dopamine Activity. Journal of Neuroscience, 2006, 26, 10789-10795.	3.6	259
32	Placebo Effects Mediated by Endogenous Opioid Activity on Î¼-Opioid Receptors. Journal of Neuroscience, 2005, 25, 7754-7762.	3.6	702
33	Neurobiological Mechanisms of the Placebo Effect. Journal of Neuroscience, 2005, 25, 10390-10402.	3.6	598
34	Interface of physical and emotional stress regulation through the endogenous opioid system and Î¼-opioid receptors. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2005, 29, 1264-1280.	4.8	132
35	Prosthodontic research: breaking traditional barriers. Journal of the Canadian Dental Association, 2005, 71, 332.	0.6	1
36	Introduction to study group reports. International Journal of Prosthodontics, 2005, 18, 277-9.	1.7	2

#	Article	IF	Citations
37	Taking stock: from chasing occlusal contacts to vulnerability alleles. Orthodontics and Craniofacial Research, 2004, 7, 157-161.	2.8	27
38	COMT val ¹⁵⁸ met Genotype Affects Âμ-Opioid Neurotransmitter Responses to a Pain Stressor. Science, 2003, 299, 1240-1243.	12.6	1,025
39	The search for the cause of persistent muscle pain. Journal of Pain, 2002, 3, 268-269.	1.4	3
40	Î¼-Opioid Receptor-Mediated Antinociceptive Responses Differ in Men and Women. Journal of Neuroscience, 2002, 22, 5100-5107.	3.6	344
41	Habituation of the early pain-specific respiratory response in sustained pain. Pain, 2001, 91, 57-63.	4.2	20
42	Muscle pain inhibits cutaneous touch perception. Pain, 2001, 92, 327-333.	4.2	63
43	Regional Mu Opioid Receptor Regulation of Sensory and Affective Dimensions of Pain. Science, 2001, 293, 311-315.	12.6	776
44	Chronic Orofacial Pain: Is the Puzzle Unraveling?. Journal of Dental Education, 2001, 65, 1383-1392.	1.2	12
45	Measurement of Facial Soft Tissue Mobility in Man. Cleft Palate-Craniofacial Journal, 1998, 35, 16-25.	0.9	40
46	Masticatory myalgias. Pain Forum, 1997, 6, 176-180.	1.1	29
47	Temporomandibular disordersâ€"pain outside the head and face is rarely acknowledged in the chief complaint. Journal of Prosthetic Dentistry, 1997, 78, 592-595.	2.8	45
48	The effect of experimental jaw muscle pain on postural muscle activity. Pain, 1996, 66, 215-221.	4.2	82
49	Jaw muscle pain and its effect on gothic arch tracings. Journal of Prosthetic Dentistry, 1996, 75, 393-398.	2.8	55
50	Three-dimensional unilateral method for the bilateral measurement of condylar movements. Journal of Biomechanics, 1995, 28, 1007-1011.	2.1	8
51	OCCLUSAL THERAPY IN THE TREATMENT OF TEMPOROMANDIBULAR DISORDERS. Oral and Maxillofacial Surgery Clinics of North America, 1995, 7, 129-139.	1.0	3
52	The effect of experimental muscle pain on the background electrical brain activity. Pain, 1992, 49, 349-360.	4.2	44
53	Determining the force absorption quotient for restorative materials used in implant occlusal surfaces. Journal of Prosthetic Dentistry, 1992, 67, 361-364.	2.8	88
54	PROSTHETIC REHABILITATION IN TEMPOROMANDIBULAR DISORDER AND OROFACIAL PAIN PATIENTS. Dental Clinics of North America, 1992, 36, 581-589.	1.8	6

#	Article	IF	Citations
55	The pain-adaptation model: a discussion of the relationship between chronic musculoskeletal pain and motor activity. Canadian Journal of Physiology and Pharmacology, 1991, 69, 683-694.	1.4	861